The U.S. has more thalidomide survivors than the government admits

In the early 1960s, Dr. Frances Oldham Kelsey, a pharmacologist at the FDA, played a crucial role in preventing the approval of thalidomide, a sedative linked to severe birth defects, for general use in the United States. Despite pressure from the pharmaceutical company William S. Merrell, Kelsey insisted on more rigorous testing, which ultimately led to stricter drug regulations. Although thalidomide was not officially approved, it was still distributed to thousands of U.S. patients, including pregnant women, resulting in children born with deformities. These individuals, now adults, seek acknowledgment from the government for their suffering. The case highlights the importance of thorough drug testing and regulation to prevent similar tragedies. QUESTION: How might the story of thalidomide influence your perspective on the importance of drug safety and regulation today?